U.S. Supreme Court Justice Antonin Scalia, FDA Commissioner Andrew C. von Eschenbach Among Featured Speakers at March 26-27, 2008, FDLI/FDA Meeting in Washington, D.C.
WASHINGTON, Jan. 9 /PRNewswire-USNewswire/ -- The Food and Drug Law Institute's 51st Annual Conference, co-sponsored with the Food and Drug Administration, will focus on the interrelationship between scientific and technological advances and food & drug law & regulation.
FDLI/FDA's March 26-27, 2008 meeting at the L'Enfant Plaza Hotel in Washington, D.C., will include a luncheon speech by U.S. Supreme Court Justice Antonin Scalia and a State of the FDA address by Commissioner Andrew C. von Eschenbach, M.D. Rep. John D. Dingell (D-Mich.) is also an invited featured speaker.
As noted in the recent FDA Science and Mission at Risk Report (http://backweb.fdli.org/pdf/FDAScience.pdf), scientific advances often pose significant policy issues and challenges for legal and regulatory systems. While government agencies are authorized to develop and implement policies that stimulate scientific advances for the benefit of public health, they are also mandated to ensure safety, effectiveness and affordability. The FDLI annual meeting, Scientific Revolution and Legal Evolution: Keeping Pace with Science & Policy Issues in Food and Drug Law, focuses on these dynamic tensions while informing attendees about the impact of recent wide-sweeping food and drug legislation.
Other featured speakers include:
J. Scott Ballenger, Partner, Latham & Watkins;
Brian J. Donato, Partner, Hyman, Phelps & McNamara;
Lillian J. Gill, Director, Office of Compliance, Centers for Devices and Radiological Health, FDA;
Jesse L. Goodman, M.D., Director, Center for Biologics Evaluation and Research, FDA;
Peter Barton Hutt, Partner, Covington & Burling;
Gerald F. Masoudi, Associat
|SOURCE Food and Drug Law Institute|
Copyright©2008 PR Newswire.
All rights reserved